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Abstract
Background: Heat shock protein 90 (HSP90) is a molecular chaperone responsible for the conformational maintenance of a
number of client proteins that play key roles in cell cycle arrest, DNA damage repair and apoptosis following radiation.
HSP90 inhibitors exhibit antitumor activity by modulating the stabilisation and activation of HSP90 client proteins. We
sought to evaluate NVP-AUY922, the most potent HSP90 inhibitor yet reported, in preclinical radiosensitization studies.
Principal Findings: NVP-AUY922 potently radiosensitized cells in vitro at low nanomolar concentrations with a concurrent
depletion of radioresistance-linked client proteins. Radiosensitization by NVP-AUY922 was verified for the first time in vivo in
a human head and neck squamous cell carcinoma xenograft model in athymic mice, as measured by delayed tumor growth
and increased surrogate end-point survival (p=,0.0001). NVP-AUY922 was shown to ubiquitously inhibit resolution of
dsDNA damage repair correlating to delayed Rad51 foci formation in all cell lines tested. Additionally, NVP-AUY922 induced
a stalled mitotic phenotype, in a cell line-dependent manner, in HeLa and HN5 cell lines irrespective of radiation exposure.
Cell cycle analysis indicated that NVP-AUY922 induced aberrant mitotic entry in all cell lines tested in the presence of
radiation-induced DNA damage due to ubiquitous CHK1 depletion, but resultant downstream cell cycle effects were cell line
dependent.
Conclusions: These results identify NVP-AUY922 as the most potent HSP90-mediated radiosensitizer yet reported in vitro,
and for the first time validate it in a clinically relevant in vivo model. Mechanistic analysis at clinically achievable
concentrations demonstrated that radiosensitization is mediated by the combinatorial inhibition of cell growth and survival
pathways, ubiquitous delay in Rad51-mediated homologous recombination and CHK1-mediated G2/M arrest, but that the
contribution of cell cycle perturbation to radiosensitization may be cell line specific.
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Introduction
HSP90 is a ubiquitously expressed molecular chaperone which
exists as part of a larger complex consisting of HSP70 and co-
chaperones such as Cdc37, p23, AHA1, Hip and Hop [1,2]. The
normal function of HSP90 in cellular homeostasis is the
conformational maintenance of a pool of client proteins and, as
such, it is essential for their sustained activity. The finding that
HSP90 maintains the stability and activity of a range of
oncoproteins which give rise to the malignant phenotype [3] has
resulted in the concept of chaperone addiction; i.e. tumor cells in
which continued oncogenic activity is reliant on the underlying
molecular chaperone machinery of the cell [4]. Key amongst
HSP90’s oncogenic clientele are receptor tyrosine kinases, cyclin-
dependent kinases, hypoxia-linked factors and telomerase [3,4].
Many of these client proteins have been identified to play key roles
in cell cycle arrest, DNA damage repair and apoptosis in response
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in the field of radiosensitization [7].
The great advantage of HSP90 targeted therapies is the
simultaneous, combinatorial depletion of many potentially onco-
genic factors by a single therapeutic agent. Early HSP90 inhibitors
were based on the natural compound geldanamycin, which gave
rise to a number of analogs with improved pharmacological
properties, including the first-in-class analog 17-AAG. Preclinical
HSP90 mediated radiosensitization has been reported with both
geldanamycin and its derivatives (17-AAG and 17-DMAG) [8,9]
as well as the orally bioavailable PU3 purine scaffold derivative
BIIB021 [10]. Geldanamycin family compounds have been shown
to radiosensitize a diverse array of tumor-derived cell lines in vitro,
including squamous cell [11], prostate [8,9,12], lung [13],
colorectal [13–15], cervical [16,17], bladder [14] and pancreatic
carcinomas [9], glioma [8,17] and melanoma [14]. In addition,
radiosensitization of human vascular endothelial cells has been
reported [18].
In vivo radiosensitization has been shown in human cervical [16],
prostate [12] and head and neck squamous cell carcinoma
(HNSCC) [10] tumor xenograft models. Response has been
shown to be dependent on cell division, since fibroblasts that
originally were not radiosensitized by geldanamycin or 17-AAG
became sensitive upon transformation by HPV16 E7 or E6
[14,16]. The geldanamycin derivatives 17-AAG and 17-DMAG
have, thus far, proven useful in providing mechanistic insights,
preclinical and clinical validation of biomarkers of HSP90
inhibition and identification of other beneficial effects such as
anti-angiogenic properties [19,20].
Until now, the success of 17-AAG (tanespimycin) in phase II
clinical trials has been limited. While phase I trials showed signs of
clinical activity [21–23], phase II trials have been less conclusive,
with evidence of response observed in metastatic melanoma [24]
but not for metastatic prostate [25] or papillary and clear cell renal
carcinomas [26]. Phase I studies of 17-DMAG have shown HSP72
induction and promising signs of clinical activity [27]. In this
regard, the need for HSP90 inhibitors of greater potency and
efficacy is evident and has given rise to a number of synthetic
alternatives, one of the most promising of which is NVP-AUY922
(VER-52296). This agent is a fully synthetic isoxazole resorcinol-
based HSP90 inhibitor and is the most potent NH2-terminal
HSP90 inhibitor yet described [20,28]. NVP-AUY922 has been
shown to have anti-proliferative effects in vitro against a panel of
breast cancer cell lines and primary cultures [29], multiple
myeloma [30], prostate [20,28], colon, melanoma, glioma
[28,31] and HUVEC cell lines [20]. Efficacy as a single agent
has been seen in vivo in BT-474 breast [29], HCT116 colorectal
[28] and U87MG glioblastoma [31] xenografts in mice.
NVP-AUY922 has been shown to overcome a number of
limitations associated with 17-AAG, exhibiting selectivity for
HSP90, increased solubility, an absence of the hepatotoxicity-
linked quinone moiety and independence of 17-AAG-linked
NQO1 metabolism [20]. Also important is the substantially
increased potency, with a 60-fold decrease in IC50 values for
fluorescence polarisation binding assays and 10-fold decrease in
HCT116 GI50 concentrations compared with 17-AAG [28].
In this report, we describe the ability of NVP-AUY922 to
radiosensitize cervical, colorectal and HNSCC cell lines with
greater potency than any previously reported HSP90 inhibitor.
We also report confirmation for the first time of radiosensitization
by NVP-AUY922 in vivo. Mechanistic analysis in vitro indicates that
radiosensitization is likely to be combinatorial in nature, with
inhibition of growth signalling, radiation-induced DNA damage
repair by homologous recombination and perturbation of cell
cycle progression into mitosis all likely contributing factors.
Materials and Methods
Cell Culture Conditions
HCT116 (colorectal carcinoma) and HeLa (uterine cervical
carcinoma) were obtained from the ATCC. LICR-LON-HN3 and
LICR-LON-HN5 (HNSCC) cell lines, from here on referred to as
HN3 and HN5 for brevity, were obtained from stocks in the
Targeted Therapy Lab, The Institute of Cancer Research,
London, United Kingdom. Cells were cultured in DMEM
(Invitrogen, Paisley, UK) supplemented with 2 mM L-glutamine
and 1% penicillin/streptomycin in a humidified incubator at 37uC
with 5% CO2. Cells were subcultured at 80–90% confluency and
routinely tested for the presence of mycoplasma using the eMyco
PCR kit from IntroBio (Seongnam-Si, South Korea). Cell line
stocks were authenticated by short tandem repeat profiling carried
out by Bio-Synthesis Inc. (Texas, US).
Compounds and Irradiation
NVP-AUY922 was kindly donated by Novartis in the form of
the mesylated salt and was reconstituted in DMSO before storage
at 220uC. 5% dextrose was used as a vehicle for in vivo
intraperitoneal delivery. Irradiation was carried out using an
AGO 250 kV X-ray machine (AGO, Reading, UK).
Clonogenic Assay
Cell survival was measured by colony formation assay. Cells
were trypsinised, diluted and counted before seeding in 6-well
dishes at varying cell densities. After cells had attached they were
treated with NVP-AUY922 or DMSO control for 24 h before
irradiation with 0–8 Gy. After 10–14 days, colonies were fixed and
stained in 7% ethanol, 0.5% crystal violet, with colonies
containing more than 50 cells counted. Colony counting was
performed manually and using the Oxford Optronics Colcount
system (Oxford, UK). Percent cell survival was estimated by
normalizing data to drug-free unirradiated control. Surviving
fraction was derived using the formula: Number of Colonies/
Number of cells plated x PE (where PE equals Number of
Colonies/Number of cells plated in drug-free unirradiated
control).
In Vivo Human Xenograft Model and Ethics Statement
All animal studies were conducted in accordance with NCRI
(National Cancer Research Institute) guidelines [32]. All animal
research was reviewed and approval under the ethical review
process by the Institute of Cancer Research Ethics Committee.
These experiments were performed under the authority given by
UK Home Office Project License PPL 70/6890. HN3 cells were
implanted by injection of 3610
6 cells into the right flank of 6-week
old female CD-1 nude mice (Charles River, UK). Mice were
randomised into experimental groups after tumors had achieved a
maximum diameter of 5–8 mm with differing tumor volumes
evenly distributed between groups (mean starting volumes: control
116.1644.2; NVP-AUY922 10 mg/kg only 130.1666.9; fraction-
ated radiation only 133.7641.6; NVP-AUY922 10 mg/kg plus
radiation 139.7636.6). NVP-AUY922 in 5% dextrose was
injected intraperitoneally in a volume of 200 ml at the desired
time points and irradiation carried out post-NVP-AUY922
administration. Briefly, animals were anaesthetized by intraperi-
toneal injection of 100 ml of a 1:1:4 mixture of Hypnorm (fentanyl
citrate 0.315 mg/mL, fluanisone 10 mg/mL) from Janssen-Cilag
Ltd (High Wycombe, UK), HypnovelH (midazolam 5 mg/mL)
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BP from Fresenius Health Care Group (Basingstoke, UK). Mice
were positioned under lead shielding with subcutaneous tumors
only exposed to localized radiation. Perpendicular diameter
measurements of each tumor were taken twice weekly with
volumes calculated using the formula (width x width x length)/2.
Tumors were followed until the maximum diameter reached
15 mm (humane end point), or ulceration. Tumor and liver
samples, with liver as a representative normal tissue sample, were
snap frozen following harvesting for subsequent western blot
analysis.
Western Blotting and Antibodies
Cells were seeded in 10 cm dishes and allowed to recover for
24 h before NVP-AUY922 addition. Media, washes and cells were
subsequently harvested with PBS containing 2 mM Na3VO4 and
centrifuged at 1,200 rpm before lysis in RIPA buffer containing
50 mM Tris.HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
deoxycholate and 0.1% SDS. Samples were thawed on ice,
centrifuged at 14,000 rpm for 20 min at 4uC and supernatants
quantified by BCA assay from Pierce (Leicestershire, UK). 20–
30 mg total protein were separated by reducing 10% SDS-PAGE,
transferred to PVDF membrane (GE Healthcare, Bucks, UK),
blocked with 5% non-fat dry milk in PBS for 1 h and probed with
the following primary antibodies in 5% BSA and 0.1% Tween-20:
rabbit anti-HSP72 from Stressgen (Exeter, UK), rabbit anti-
ErbB2, rabbit anti-cRAF from Santacruz (CA, USA), rabbit anti-
pErbB2, rabbit anti-pCHK1, rabbit anti-CHK1, rabbit anti-
pAKT, rabbit anti-AKT and rabbit anti-pH2ax were all
purchased from Cell Signalling (MA, USA), rabbit anti-p-histone
H3 was purchased from Upstate-Millipore (UK). Loading was
quantified using mouse anti-c-tubulin from Sigma (Poole, UK).
Secondary antibodies used were goat anti-mouse IgG HRP from
Jackson Immunoresearch (Suffolk, UK) and donkey anti-rabbit
IgG from GE Healthcare. Chemiluminescent detection was
carried out using immobilon western substrate from Millipore
according to the manufacturer’s instructions. In vivo samples were
processed by homogenisation in RIPA buffer using a PrecellysH24
homogeniser from Bertin Technologies (Montigny, France) before
SDS-PAGE and western analysis as for in vitro samples.
DNA Damage Repair
Cells were seeded at 1610
5 on 35 mm dishes with an inner
10 mm glass well from Mattek (MA, USA) and allowed to recover
for 24 h. Cells were treated with NVP-AUY922 or DMSO only
for 24 hours and irradiated with 4 Gy. At 4 and 24 hours samples
were fixed in 10% formalin for 30 minutes at room temperature.
Cells were subsequently washed, permeabilised in 0.2% Triton X-
100, treated with DNase I from Roche (West Sussex, UK) at 37uC
for 1 hour, rinsed in PBS and blocked in 1% BSA, 2% FCS in PBS
for 1 hour. Cells were stained with rabbit anti-phopho-H2ax (Cell
Signalling) and mouse anti-RAD51 (Genetex, CA, USA) and
visualized with Alexafluor 488 goat anti-rabbit secondary and
Alexafluor 546 goat anti-mouse (Invitrogen, Paisley, UK). Nuclei
were counterstained with TO-PRO-3 iodide from Invitrogen and
nuclear dsDNA damage visualised using a Zeiss LSM710 inverted
confocal microscope (Carl Zeiss, Jena, Germany).
Nuclear Volume and Micronuclei
Cells were seeded at 1610
5 in 6 cm or Mattek dishes and
allowed to recover for 24 h. NVP-AUY922 or DMSO vehicle was
added for 24 hours before irradiation. Cells were fixed in 10%
formalin for 30 min, rinsed in PBS and nuclei stained for 5 min
with 49, 6-diamidino-2-phenylindole (DAPI) from Sigma (Poole,
UK). Z-stack confocal microscopy acquisition was used in
conjunction with Volocity v5.2 (Perkin Elmer) image processing
and analysis software to quantify nuclear volume as well as the
presence of multinucleated cells and micronuclei.
Mitotic Index and Cell Cycle Analysis
Cells were seeded in 10 cm dishes and allowed to recover for
24 h. Vehicle or NVP-AUY922 was added at the concentrations
indicated. After 16 h cells were irradiated with 4 Gy. At time
points post-irradiation, media and trypsinised cells were harvested
and immediately processed on ice, washed in PBS, resuspended in
1 ml of ice-cold PBS at 5610
5 cells/ml and syringed into 4 ml of
ice-cold ethanol while vortexing. After fixation, cells were washed
in PBS, blocked in 1% BSA, 2% FCS in PBS for 1 hour before
staining with 1 mg/ml rabbit anti-phospho- histone H3 from
Millipore-Upstate (Watford, UK) overnight at 4uC followed by
goat anti-rabbit Alexafluor-488 secondary for 2 hours at room
temperature. Cells were resuspended in 500 ml of 100 mg/ml
RNase A and 10 mg/ml propidium iodide (Sigma), before analysis
by flow cytometry using an LSR II from BD Biosciences (Oxford,
UK).
Statistical Analysis
Graphpad prism (version 5.0c) was used to carry out statistical
analysis. Paired or unpaired two-tailed student t-test was selected
for parametric analysis. Analysis of surrogate end point data was
carried out using the Mantel-Cox log-rank test.
Results
Radiosensitivity induced by NVP-AUY922 in vitro
The ability of NVP-AUY922 to radiosensitize HeLa (uterine
cervical carcinoma), HN3, HN5 (HNSCC) and HCT116
(colorectal carcinoma) cells in vitro was assessed by clonogenic
assay (Fig. 1). These cell lines were selected as representative of
tumor types for which radiotherapy is a curative treatment option
in the clinic as well as the prevalence of common oncogenic
molecular characteristics of relevance to HNSCC and radioresis-
tance (EGF-R overexpression, HN5 and HN3; HPV status, HeLa;
activated kRAS and PI3K catalytic subunit, HCT116). The
highest concentration of NVP-AUY922 alone which did not
reduce clonogenic survival was determined for each cell line. For
all four cell lines, these concentrations were in the low nanomolar
range: 1 nM for HeLa, 3 nM for HN3 and HN5, and 5 nM for
HCT116. Radiation survival curves generated with and without
NVP-AUY922 (Fig. 1) show statistically significant radiosensitiza-
tion for all four cell lines in the presence of NVP-AUY922 (p-
values at 2 Gy between drug free and treated are, HeLa p=0.004,
HN3 p=0.0157, HN5 p=0.0023 and HCT116 p=0.0094).
Radiosensitization by 17-AAG has been reported in the literature
within the range of 30–200 nM (see discussion). Consistent with
this, radiosensitization by 17-AAG in the panel of four cell lines
used was observed at 100 nM (Fig. S1A). This indicates that NVP-
AUY922 is a substantially more potent radiosensitizer than 17-
AAG in vitro (Fig. S1A), in the low nanomolar range and at
clinically relevant radiation doses, i.e. 2 Gy.
NVP-AUY922 radiosensitizes in vivo in a HNSCC human
xenograft model
To assess the efficacy of NVP-AUY922 as a radiosensitizer in
HNSCC in vivo, a HN3 human xenograft model in CD-1 nude
mice was selected. Due to the routine clinical administration of
radiation in fractions, 10 mg/kg NVP-AUY922 was given
intraperitoneally on four consecutive days, followed by three
Mechanisms of Radiosensitization by NVP-AUY922
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tion on days one to three (Fig. 2A). Ten mg/kg NVP-AUY922 was
selected as a suboptimal dose based on previously reported activity
in vivo [29]. Tumors were measured every 2–3 days with the
resulting measurements expressed relative to baseline tumor
volumes at the commencement of treatment (Fig. 2B). A
maximum tumour diameter of 15 mm was used as a humane
Figure 1. NVP-AUY922 decreases clonogenic survival due to
ionising radiation in vitro. Clonogenic assay was utilised to assess
radiosensitization by NVP-AUY922 in vitro against the uterine cervical
carcinoma and colorectal carcinoma cell lines HeLa and HCT116 and the
HNSCC cell lines HN3 and HN5. After plating at an appropriate seeding
density and allowed to attach, cells were exposed to NVP-AUY922 at
the concentrations indicated per cell line for 24 h to facilitate
downstream effects of HSP90 inhibition to occur. Cells were subse-
quently exposed to ionising radiation at the doses indicated. Colony
formation was determined at 10 to 14 days after irradiation and
surviving fractions calculated relative to plating efficiencies for vehicle
only non-irradiated cells. Data 6 SEM with statistical analysis carried out
by two-tailed t-test between surviving fractions at each radiation dose,
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0035436.g001
Figure 2. Sub-optimal dosing of NVP-AUY922 delays tumor
growth and increases time to surrogate endpoint in vivo in
conjunction with ionising radiation. Radiosensitization due to
NVP-AUY922 was assessed in vivo in a human xenograft model. HN3
cells were allowed to achieve a tumor volume of 5–8 mm after
implantation in the right flank and evenly distributed into four
treatment groups with matching average tumor volumes; vehicle only
control (n=8); NVP-AUY922, four doses of 10 mg/kg each (n=9); 9 Gy
ionising radiation fractionated in three doses of 3 Gy (n=9); NVP-
AUY922 and ionising radiation (n=8). (A) Scheduling of four rounds of
10 mg/kg NVP-AUY922 or vehicle only was administered by interper-
itonal injection, followed by fractioned tumor-targeted radiotherapy of
3 Gy each to a cumulative total of 9 Gy on days one to three. Tumor
sizes were measured every 3–4 days with resulting percentage baseline
tumor volume (B) and percentage surrogate endpoint (C) shown. Data
represents 6 SEM. Mantel-Cox log-rank test carried out for statistical
analysis of surrogate endpoint data (p=0.0002).
doi:10.1371/journal.pone.0035436.g002
Mechanisms of Radiosensitization by NVP-AUY922
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volumes unadjusted for baseline are shown in supporting
information (Fig. S1B).
NVP-AUY922 10 mg/kg alone had negligible effect in reducing
tumor volume over the duration of the experiment, with growth
rates similar to those observed in the vehicle treated control group
(Fig. 2B). As expected, a significant delay in tumor growth was
observed in the fractionated radiation only group, up until
approximately day 15–20. At this point, tumor growth accelerated
with the percentage reaching surrogate survival endpoint rapidly
increasing from day 35 onwards. The radiation plus NVP-
AUY922 group was the only group in which a drop in tumor
volume was observed at any stage, this was maintained until day
18 at which point tumor volume had recovered to baseline levels.
From this point, growth for radiation plus NVP-AUY922 was
significantly slower than that observed for radiation alone (Fig. 2B).
This was mirrored in the significantly increased time to surrogate
survival endpoint (Fig. 2C) of the NVP-AUY922 plus radiation
group compared to fractionated radiation alone (p=0.0002). The
NVP-AUY922 only group exhibited an increase in median time to
surrogate survival endpoint from 14 to 21 days, while in
conjunction with fractionated radiation median time to surrogate
survival endpoint increased by 14.5 days over fractionated
radiation alone (35 to 49.5 days) with one animal cured at the
termination of the experiment. The plateau effect observed after
35 days was due to loss of mice with rapidly growing tumours
having reached the surrogate survival humane end point (Fig. 2C),
as stipulated in UK NCRI animal welfare guidelines [32].
Biomarker response to NVP-AUY922
It has previously been reported that successful HSP90 inhibition
by both 17-AAG [33] and NVP-AUY922 [20] generates a
molecular signature characterised by induction of HSP72 and
depletion of HSP90 client proteins. Depletion of radioresistance-
linked client proteins has been shown to occur at concentrations
correlating to radiosensitization. Therefore, NVP-AUY922-medi-
ated depletion of AKT, ErbB2 and cRAF was investigated in
HeLa and HN3 cells (Fig. 3A).
Biomarker response in both HeLa and HN3 cells in vitro was
observed to be similar at comparable GI50 doses. HSP72 was
clearly upregulated at 16GI50 in both HeLa and HN3 cancer cell
lines and substantially upregulated at 5–106GI50 doses. Concur-
rently, cRAF (band indicated by arrow), a component of the RAS-
RAF-MEK-ERK pathway and total- and phospho-AKT were
minimally decreased at 16GI50 with substantial depletion
observed at 5–106GI50 values. Total- and phospho-ErbB2
displayed the greatest sensitivity to HSP90 inhibition by NVP-
AUY922, with a clear depletion observable at 16GI50 concentra-
tions in both HeLa and HN3 cell lines. Tumor samples were
harvested at the point of administration of the final radiation
fraction to determine biomarker response in vivo. Increased HSP72
was clearly visible in tumors of the NVP-AUY922 and radiation
combined group (Fig. 3B). Investigations into in vitro HSP72
upregulation by radiation combined with NVP-AUY922 indicated
minor upregulation of HSP72 at 4 h post-radiation alone, in
HeLa, HN3 (Fig. 3C) and HN5 (Fig. S2) cell lines. Minor
fluctuations in HSP72 due to radiation only were observed in time
course analysis in HeLa and HN3 cancer cells up to 24 and 28 h
post-radiation (Fig. 3D; Fig. S2C). However, any increases
observed were insignificant when compared to the increase in
HSP72 observed in the presence of HSP90 inhibitor (Fig. 3D),
with NVP-AUY922 shown clearly to elicit ErbB2 depletion and
drive aberrant mitotic progression.
NVP-AUY922 delays Rad51 foci formation and
subsequent resolution of radiation-induced DSB repair
HSP90 inhibition by the geldanamycin class of inhibitors has
been shown previously to interfere with double-strand DNA break
(DSB) resolution [15,17]. Due to the more selective nature of
NVP-AUY922 as an HSP90 inhibitor, we sought to verify the
ability of NVP-AUY922 to abrogate effective DSB repair and
impair Rad51-mediated homologous recombination. Quantifica-
tion of phospho-H2ax (pH2ax) foci, a marker of DNA DSBs, and
focal formation of the homologous recombination protein Rad51
were carried out by confocal microscopy. Representative images of
pH2ax and Rad51 focal staining at 24 h are shown for both HeLa
and HN3 cell lines (Fig. 4A) alongside quantification of pH2ax
(Fig. 4B; Fig. S3A) and Rad51 foci (Fig. 4C; Fig. S3B) in HeLa,
HN3, HN5 and HCT116 cell lines.
NVP-AUY922 delayed resolution of radiation-induced DSB
repair in all four cell lines tested, as shown by increased residual
pH2ax foci at 24 h. NVP-AUY922 alone, at GI50 concentrations
in all four cell lines (Fig. 4B; Fig S3), resulted in a small increase in
pH2ax focal formation at 4 h. Foci remained constant and did not
increase from 4 h to 24 h. In HeLa (Fig. 4B), HN5 and HCT116
(Fig. S3), the addition of NVP-AUY922 to 4 Gy irradiation
indicated a small but statistically insignificant increase in focal
formation at 4 h. Tracking the decrease in pH2ax foci between 4
and 24 h as indicative of DSB resolution, NVP-AUY922 reduced
the resolution of radiation-induced DSB in all four cell lines tested.
pH2ax foci remaining at 24 h due to the combination of NVP-
AUY922 and radiation increased over radiation alone from 1.9 to
3.8 foci per cell in HeLa, 4.5 to 8.5 foci per cell in HN3 (Fig. 4B),
5.1 to 7.4 foci per cell in HN5 and 1.0 to 5.6 foci per cell in
HCT116 (Fig. S3). Co-inciding with this abrogation of radiation-
induced DSB repair, NVP-AUY922 was shown to slow the
progression of Rad51-focal formation in all four cell lines. NVP-
AUY922 caused a decrease in Rad51 positive nuclei 4 h post
radiation, scored as greater than 3 Rad51 foci, in all four cell lines
tested (Fig. 4C; Fig. S3B). At 24 h post irradiation, the opposite
was true, with an increase in Rad51 positive cells observed due to
the addition of NVP-AUY922. This increase at 24 h was from 1 to
8% in HeLa cells, 18 to 40.7% in HN3 cells, 9.6 to 24.3% (Fig. 4C)
in HN5 cells and zero to 9.2% in HCT116 cells (Fig S3B).
Increased micronuclei and nuclear volume due to
irradiation in the presence of NVP-AUY922
The definition of mitotic catastrophe [34,35] stipulates that
attempts at aberrant chromosome segregation are followed by
either caspase-2 dependent apoptosis or cells failing in apoptotic
execution likely to result in aneuploidy. In order to assess these
facets of mitotic catastrophe in respect of NVP-AUY922,
micronuclei and nuclear volume at 48 h were quantified as
morphological measures of aberrant chromosomal segregation and
aneuploidy, respectively.
Quantification of micronuclei expressed as number of micro-
nuclei per 100 cells (Fig. 5A) revealed that NVP-AUY922 in
combination with radiation resulted in increased micronuclei
formation over radiation alone which was greater than additive in
all four cell lines, i.e. the increase observed when both were
combined was greater than that observed were the increase due to
each in isolation to be added together. Drug only increases in
micronuclei over controls were zero for HeLa, 8 for HN3, 2.6 for
HN5 and 5.5 for HCT116. The addition of GI50 concentrations of
NVP-AUY922 to radiation over radiation alone resulted in an
increase in micronuclei formation from 5.6 to 13.2 in HeLa cells, 7
to 16.7 in HN3 cells, 6.1 to 10.6 in HN5 cells and 9.5 to 19.1 in
Mechanisms of Radiosensitization by NVP-AUY922
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staining at 24 h post irradiation showed greater than additive
increases due to NVP-AUY922 combined with radiation in all
four cell lines (Fig. 5C; Fig. S4). NVP-AUY922 alone did not alter
the level of cells positive for pH2ax-containing micronuclei from
those observed in controls.
Quantification of nuclear volume 48 h post irradiation (Fig. 5B)
revealed nuclear volume increased significantly for HeLa and
HN5 cells due to NVP-AUY922 alone while increases were
minimal in HN3 and HCT116 cells. In HN5 cells, radiation and
NVP-AUY922 combined resulted in an increase above radiation
alone in HN5 cells, while HeLa, HN3 and HCT116 cell lines all
showed a greater than additive increase in nuclear volume due to
the combination of NVP-AUY922 and radiation.
NVP-AUY922 inhibits CHK1-mediated G2 arrest in the
presence of radiation-induced DNA DSBs
HSP90 inhibitors have been shown to inhibit radiation-induced
G2 arrest [12,15]. Therefore, we sought to verify the ability of
NVP-AUY922 to drive aberrant mitotic entry in the presence of
radiation-induced DNA damage (Fig. 6A) and downstream
consequences with respect to p53 status (HCT116 p53wt, Hela
HPV-positive, HN5 and HN3 p53 mutant). In both HeLa and
HN3 cells, radiation only at 4 h resulted in increased pH2ax
(DNA damage), increased pS345 CHK1 (G2/M checkpoint
arrest) and decreased phistone H3 (mitotic marker). In both of
these cell lines, NVP-AUY922 abrogated radiation-induced pS345
CHK1 with a concomitant increase in phistone H3, indicating
aberrant mitotic entry in the presence of radiation-induced DNA
Figure 3. Molecular signature of NVP-AUY922 in combination with radiation. (A) To confirm depletion of HSP90 client proteins linked to
radioresistance, levels were assessed in vitro in HeLa and HN3 cell lines by western blot. Cells were treated with vehicle only, or the concentrations of
NVP-AUY922 indicated for 24 h, followed by reducing SDS-PAGE of 30 mg whole cell lysate and western blot detection of the HSP90 client proteins
shown. (B) Levels of HSP72 28 h post NVP-AUY922 treatment and phospho-ErbB2 24 h post NVP-AUY922 treatment were determined by
densitometry of three independent experiments (see Fig. S2A). (C) HeLa and HN3 cells were pre-treated with NVP-AUY922 for 24 h at the
concentrations indicated. Cells were irradiated with 4 Gy or 10 Gy and 4 h later whole cell lysates harvested and probed for HSP72 by western blot.
(D) Cells were pre-treated with 10 nM NVP-AUY922 for 24 h with 4 Gy of radiation delivered at the 0 hour time point. At the subsequent time points
indicated, whole cell lysates were harvested and probed for total-ErbB2, phospho-histoneH3 and HSP72. (E) Tumor samples were harvested at the
point of final irradiation to determine response to NVP-AUY922 in vivo. Tissue samples were homogenised and 30 mg of protein probed for HSP72 by
reducing SDS-PAGE and western blot. c-tubulin was probed as loading control in all blots shown.
doi:10.1371/journal.pone.0035436.g003
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trations corresponded, in part, to loss of total-CHK1 (Fig. 6B).
Quantification of phistone H3 positive cells (mitotic index) by
flow cytometry showed NVP-AUY922 abrogated the radiation-
induced decrease in mitotic index in all four cell lines (Fig. 6C).
Two distinct phenotypes were identifiable, HeLa and HN5 cell
lines showed a significant increase in mitotic index due to NVP-
AUY922 alone which was maintained even after radiation, while
no increase due to drug alone was observed for HN3 and HCT116
and abrogation of G2/M arrest was less significant than for HeLa
and HN5.
Downstream analysis of cell cycle perturbation due to CHK1
abrogation revealed markedly disparate outcomes. HeLa (HPV-
positive) cells 48 h post-irradiation showed an increase in .4N
cells from 7.4% in 4 Gy only samples to 14.5 and 15.5% due to
the addition of 10 and 20 nM NVP-AUY922, respectively
(Fig. 6D), with drug alone causing no increase. 20 nM NVP-
AUY922 in combination with radiation resulted in an apoptotic
subG1 population substantially greater than that observed for
4 Gy or drug only. Increasing subG1 and .4N was at the expense
of G1 but not G2 or S phase (Fig. S5), indicating failed mitotic
progression. HCT116 (p53 wild-type), the most resistant cell line
to NVP-AUY922 in our panel, showed little cell cycle perturbation
by NVP-AUY922 at 48 h in the presence or absence of radiation
except for accumulation in G1 at the expense of S phase, consistent
with G1 arrest (Fig. 6D; Fig. S5B).
The cell cycle profiles of HN3 and HN5 differ from HeLa or
HCT116 in that they are both highly affected by either radiation
alone (HN3) or NVP-AUY922 alone (HN5). HN3 cells show a
high propensity to form .4N cells due to radiation alone, with
NVP-AUY922 combined with radiation actually resulting in a
decrease in the .4N population (Fig. 6D), with a concurrent
increase in the G1 phase (Fig. S5B). NVP-AUY922 alone causes a
minimal increase in subG1 populations for HN3 and no impact on
the subG1 population above that already induced by radiation.
HN5 cells exhibit a high .4N population under control
conditions, one that remains unaltered by 4 Gy or NVP-
AUY922. HN5 cells are highly sensitive to NVP-AUY922-induced
increase in subG1 with radiation and NVP-AUY922 combinations
resulting in similar subG1 values to radiation-free drug concen-
trations.
Discussion
Use of HSP90 inhibition as an approach to radiosensitization
was first investigated by Tofilon and colleagues. 17-AAG was
shown to radiosensitize prostate cancer and glioma cell lines
exhibiting the now familiar molecular signature [20,33] of
depletion of radioresistance markers and HSP90 client proteins
AKT, ErbB2 and cRAF [8]. Since then, alternative HSP90
inhibitors have been developed including other geldanamycin
derivates such as 17-DMAG, IPI-504 and fully synthetic inhibitors
such as BIIB021, SNX-5422, STA-9090 and KW-2478. Thus far,
radiosensitization effects by this group of compounds have been
confined to geldanamycin family compounds and the purine
analog BIIB021. Geldanamycin or its analogs have been shown to
radiosensitize in vitro an array of cancer cell lines from many tissue
origins [9,11–14,16,18], proving the broad therapeutic applicabil-
ity of HSP90 inhibitors as radiosensitizers.
Numerous studies have verified client protein depletion at
radiosensitizing concentrations of geldanamycin [13,14,16], 17-
AAG [11,18], 17-DMAG [9,12] and BIIB021 [10]. This is also
true for NVP-AUY922, with depletion of radioresistant client
proteins ErbB2, AKT and cRAF occurring at 5–10 nM for HeLa
and HN3 cell lines (Fig. 3A), with depletion of total-ErbB2 and
decreasing phospho-ErbB2 signalling identifying it as the HSP90
client protein most effected by NVP-AUY922.
Figure 4. NVP-AUY922 delays radiation induced Rad51 foci
formation and DNA damage repair. HeLa and HN3 cells were
plated in glass bottom dishes and after attachment exposed to NVP-
AUY922 or DMSO control. 24 h post drug-treatment cells were mock
irradiated or irradiated with 4 Gy, 4 h and 24 h post-irradiation cells
were fixed and stained for dsDNA breaks using anti-phospho-H2ax and
Rad51 focal formation with TO-PRO-3 as nuclear counter stain. (A)
Representative images of remaining foci at 24 h are shown for HeLa
and HN3 cells, area shown represents 60 mmb y6 0 mm. (B) Mean
phospho-H2ax foci per-cell for both HeLa and HN3 at 4 h and 24 h post
irradiation was quantified in three independent experiments consisting
of phospho-H2ax counts for 150 cells per experiment. (C) Rad51 foci
were quantified in two independent experiments with nuclei contain-
ing greater than 3 Rad51 foci scored as positive. Values stated are 6
SEM for phospho-H2ax, 6 SD for Rad51. Statistical analysis by student t-
test between groups indicated, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0035436.g004
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ranges from 50–200 nM for geldanamycin [13,14,16], 30–
200 nM for 17-AAG [11,16,18], 10–50 nM for 17-DMAG
[9,12] and 125–200 nM for BIIB021 [10]. The effective
radiosensitization doses of 1–5 nM shown in Figure 1 indicate
NVP-AUY922 to be the most potent in vitro HSP90-targeted
radiosensitizer yet reported.
Only three previous studies have described in vivo radiosensiti-
zation by HSP90 inhibitors. These have included studies of
cervical, prostate and HNSCC human tumor xenograft models
with varying dose and radiation schedules. 17-AAG has been used
in single and multiple doses of 150 and 125 mg/kg, respectively,
with single fractions of 12 Gy and fractionated radiation (562 Gy)
[16]. 17-DMAG was administered in two 50 mg/kg doses with
5 Gy given 12 h after final dosing [12]. BIIB021 and 17-AAG
were administered three times weekly with 1.5 Gy given four times
per week for the 4–5 week experimental duration [10]. In all
previously published experiments, drug alone groups caused
significant tumor regression in their own right. The results shown
in Figure 2 for 10 mg/kg NVP-AUY922 are indicative of a true
radiosensitizer with similar tumor volumes for both drug and
control groups at the doses used and a significant radiosensitiza-
tion effect observed for drug plus radiation compared with
radiation alone. Significantly increased median time to surrogate
survival endpoint was observed for NVP-AUY922 combined with
radiation over radiation alone and to our knowledge this is the first
instance where survival data have been reported alongside tumor
volume data for any HSP90-based radiosensitizer. Decrease in
tumour volume has been shown previously at 10–20 mg/kg for
both BIIB021 and 17-AAG [10]. However, treatment was initiated
at tumor diameter of 2–3 mm, substantially lower than the tumor
volume used in this study.
While this is the first publication of NVP-AUY922 as a
radiosensitizer in vivo, it is also important to note that to our
knowledge this is the first validation of in vivo radiosensitization by
a HSP90 inhibitor with a high degree of selectivity for HSP90a
and HSP90b over other HSP90 family isoforms. In comparable
competitive binding fluorescence polarisation assays, IC50 values
have been shown to be; HSP90b 2166 nmol/L, GRP94
540629 nmol/L, TRAP1 85064 nmol/L for NVP-AUY922
[36]; HSP90 (alpha or beta form not stated) 119623 nM and
GRP94 124653 nM for 17AAG [37] (TRAP1 not tested).
BIIB021 binding assays for other HSP90 family isoforms have
not been reported in the literature. Additionally, in vitro
radiosensitization by 100 nM and 200 nM NVP-AUY922 has
been reported previously and was said to be similar to that of 17-
Figure 5. NVP-AUY922 in combination with radiation increases micronuclei formation and nuclear volume. The cell lines indicated
were treated with vehicle only or NVP-AUY922 for 24 h before mock irradiation or irradiation with 4 Gy. 48 h post-irradiation cells were fixed and
nuclei stained with DAPI. (A) Nuclear morphology was imaged by Z-stack confocal microscopy and the presence micronuclei of quantified for 100
cells. (B) 3-dimensional nuclear topography was constructed using Volocity image processing and analysis software and utilised to quantify increased
nuclear volume due to ionising radiation and NVP-AUY922 in 150 nuclei. (C) Confocal images at 24 h used for phospho-H2ax foci formation in figure 4
were quantified for pan-phospho-H2ax staining present in micronuclei. Values shown for quantification of a minimum of 100 nuclei. All values shown
are for three independent experiments 6 SEM with statistical analysis by student t-test between the groups indicated, *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0035436.g005
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potency observed in vitro in the present study and with the
substantially increased potency of NVP-AUY922 over geldana-
mycin analogs by other metrics of HSP90 inhibition [20,28,31,40].
Increased potency over geldanamycin family analogues is a
property of NVP-AUY922 which has been clearly shown for drug
only effects but has been missed in previous radiosensitization
studies. This difference can be attributed to NVP-AUY922
administration post-radiation [38,39], while early studies showed
the efficacy of HSP90 mediated radiosensitization was time-
dependent on pre-treatment [12,16] explaining the significant
increase in radiosensitization potency observed in this study.
Pharmacokinetic studies of NVP-AUY922 in vivo in human
melanoma and colorectal carcinoma xenografts models have
shown that 50 mg/kg NVP-AUY922 administered on five
consecutive days is capable of maintaining a dose of 3.8 to
Figure 6. NVP-AUY922 abrogates CHK1-mediated G2/M arrest in the presence of DNA damage inducing cell cycle disruption in p53
null cell lines only. The ability of NVP-AUY922 to abrogate G2 arrest in the presence of dsDNA damage was investigated by western blot and FACS
analysis in all four cell lines (p53 status: HCT116 p53wt, Hela HPV-positive, HN5 and HN3 p53 mutant). (A) HeLa and HN3 cells were pre-treated with
NVP-AUY922 for 16 h at the concentrations indicated. Cells were then mock irradiated or irradiated with 4 Gy and 4 h later whole cell lysates
harvested, 30 mg protein resolved on 10% SDS-PAGE then probed for phospho-H2ax, phospho-histone H3 and phospho-CHK1 by western blot. (B)
The effect of NVP-AUY922 on depletion of total-CHK1 was also investigated in unirradiated cells with c-tubulin probed as loading control. (C+D) Cells
were exposed to the NVP-AUY922 concentrations indicated for 16 h before mock irradiation or irradiation with 4 Gy. Cells were fixed 9 h and 48 h
post-irradiation before staining for the mitotic marker p-histone H3 and DNA content with propidium iodide. SubG1 and .4N populations were
quantified by FACS analysis. Data represents 6 SEM of three independent experiments each recording at least 10,000 events. Statistical analysis
carried out by two-tailed t-test between the groups indicated, *p,0.05 **p,0.01 ***p,0.001.
doi:10.1371/journal.pone.0035436.g006
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80 nM NVP-AUY922 for HCT116 cells equates to internal cell
concentrations of 5 mmol/L, a concentration shown to be
achievable in vivo [20]. If cellular uptake of NVP-AUY922 by
HN3 cells is in a similar range to HCT116 cells, it can be assumed
that the in vivo equivalent of 10–20 nM concentration shown to
exhibit the molecular markers of radiosensitization (Figures 3, 4, 5,
6) is achievable at dosing of 10 mg/kg based on similar
calculations. This is notwithstanding the potential radiosensitiza-
tion-independent benefits of NVP-AUY922 previously shown,
such as improvement in lung metastasis in terms of number, size
and lung volume occupied in BRAF mutant WM266.4 melanoma
xenografts, absence of lymph node metastasis in PTEN-null
human prostate carcinoma (PC3LN3) model and decreased
microvessel density in U87G PTEN-null glioblastoma xenografts
[20].
In vitro experiments have shown that HSP90 inhibitors do not
radiosensitize non-cancer cell lines [8,14,16,17,41]. In areas not
subject to radiation, but still exposed to NVP-AUY922, a clear
therapeutic window has been demonstrated between peripheral
blood mononuclear cells and primary multiple myeloma cells. In
addition, a return to active proliferation of bone marrow stromal
cells upon drug withdrawal has been seen even after 72 h
treatment with 200 nM NVP-AUY922 [30].
Single dose exposure to radiation alone was found to cause
minimal upregulation of HSP72 in vitro in HeLa cells or the two
HNSCC cell lines, HN3 or HN5, with any effect of radiation in
combination with NVP-AUY922 masked by predominant HSP90
inhibition-induced HSP72 upregulation (Fig. 3C, D; Fig. S2).
However, fractionated radiation with repeated dosing of NVP-
AUY922 did show upregulation in vivo, an effect that was seen with
neither radiation nor NVP-AUY922 alone. The occurrence of this
disparity is unsurprising, considering the substantially greater
degree of cellular stress that can be delivered in vivo due to the
combination of multiple drug administrations and fractional
radiation dosing over a number of consecutive days. This is,
however, a factor that must be taken into consideration by virtue
of the potential for HSP72-mediated anti-apoptotic effects to
reduce radiosensitization through HSP90 inhibition.
Upregulation of HSP72 by heat shock has been shown to be
protective from UVB [42], with depletion of HSP72 shown to
enhance the sensitivity of cells to genotoxic stress such as radiation
[43,44]. Even so, subtherapeutic dosing of NVP-AUY922 was
capable of mediating radiosensitization as measured by tumour
growth delay and increased survival. Even if increased doses of
NVP-AUY922 were administered as part of a regimen aiming for
curative outcomes, it is likely that higher levels of HSP72
expression would still be counterbalanced by more potent
HSP90 client protein depletion. Interestingly, evidence has shown
that HSP72 mediates protective effects against UVC radiation
through CHK1 [43]. Therefore, it is possible that potential anti-
apoptotic effects due to HSP90 inhibitor-induced upregulation of
HSP72 (as opposed to heat shock upregulation) may be
significantly abrogated by depletion of HSP90 client proteins that
are effectors of the anti-apoptotic process. Clearly, this is a
important aspect of HSP90-mediated radiosensitization that is of
great relevance to future clinical success and warrants further
studies.
The increased pH2ax foci at 24 h in radiation plus NVP-
AUY922 treated HeLa and HN3 cells (Fig. 4) demonstrates the
ability of NVP-AUY922 to delay repair of radiation-induced DNA
damage. This has previously been shown for 17-AAG in HCT116
p53 knockout, but not wild-type, cells [15] and has been suggested
by alternative methods such as DNA fragment drop-out in gel
electrophoresis [41]. The putative mechanism by which NVP-
AUY922 achieves this delay is explained by findings that early
HSP90 inhibitors deplete the critical homologous recombination
proteins Rad51 [17,41,45], BRCA2 [17,41] and impairs FANCD2
focus formation through upstream depletion of FANCA [5]. In all
four cell lines tested, NVP-AUY922 at GI50 concentrations was
found to reduce Rad51 foci 4 h post-radiation, with increased
Rad51 foci 24 h post-radiation compared to radiation alone.
These two readings taken together are indicative of a delay in
Rad51 focal assembly post-radiation, leading to a decrease in the
rate of successful homologous recombination, resulting in higher
levels of residual Rad51 foci at 24 h. This was irrespective of active
p53 (HCT116), EGF-R family overexpression (HN3, HN5) or
activated kRAS and PI3K catalytic subunit mutations (HCT116).
NVP-AUY922 has previously been reported not to deplete Rad51
[38]. However, our data conclusively show Rad51 focal formation
is ubiquitously impaired and is putatively one of the underlying
mechanisms for the broad radiosensitization observed for HSP90
inhibitors which occurs irrespective of a number of mutation
states. This prolonged DNA repair can be hypothesised to increase
the time period over which cells may trigger apoptosis as a result of
DSB DNA damage and, when combined with CHK1 depletion
(Fig. 6), it is also likely to increase the probability of an attempted
cell cycle progression with an unacceptable/unsafe burden of
DNA damage.
It has previously been shown that the G2/M checkpoint is less
rigid than previously anticipated, with cells released once the
number of DSBs drops below a threshold of approximately 20. A
delay in homologous recombination by NVP-AUY922 on its own
may simply lead to a prolonged G2/M arrest, as has been seen in
cells defective in the DNA repair nuclease Artemis [46]. The
ability to concurrently abrogate both HR and arrest, forcing
mitosis with a DSB level significantly higher than the threshold
level is likely to be the cause of the increased chromosomal
breakage shown (Fig. 5A; Fig S4). It has previously been observed
that dual deficiency in both checkpoint arrest and DNA repair
results in an increased number of chromosomal breaks than
defects in DNA repair alone [47]. The ability of 17-AAG to
radiosensitize homologous recombination-deficient cells [17]
indicates the depletion of both CHK1 and radioresistance client
proteins, such as those analysed in Fig. 3A, is also crucial to the
cumulative radiosensitization effect.
Our data indicate that NVP-AUY922-induced radiosensitiza-
tion attributable to cell cycle effects may not be ubiquitous,
particularly in respect of HNSCC. While cell line-specific G1
arrest has been reported [10], most studies have shown that cells
treated with HSP90 inhibitors in the absence of radiation
accumulate in G2/M [20,38,48–50]. Maki and colleagues used
the metaphase inhibitor colcemid as a mechanistic approach to
show geldanamycin-induced abrogation of CHK1-mediated G2
arrest, as measured by M phase accumulation due to colcemid
[15]. Data presented in Figure 6 indicate a substantial, but cell
line-specific, accumulation (HeLa and HN5) in M-phase can be
induced by NVP-AUY922 which is maintained in the presence of
radiation damage, or even enhanced in the case of HeLa cells. The
second group (HN3 and HCT116) do not display this accumu-
lation over and above normal control mitotic index levels under
any conditions.
It is unknown at this point if this is due to cell line-specific
dependence on HSP90 chaperoned client proteins involved in
mitotic progression, or depletion of client proteins such as
topoisomerase IIa [45]. Morphological indicators of nuclear
abnormalities (Fig. 5) indicate nuclear volume increases in HeLa
and HN5 due to drug alone more than in HN3 or HCT116.
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mycin in HCT116 p53 and p21 knockout models [15] as well as
more traditional radiosensitizers such as aurora B kinase inhibition
[51], do not indicate any increase due to drug alone. The opposite
is in fact true with HN3 and HCT116 showing higher levels of
micronuclei due to drug alone. All four cell lines, however, show a
clear increase in micronuclei formed due to NVP-AUY922 in
combination with radiation.
HSP90-mediated depletion of CHK1 [15,45,49,51] is clearly
ubiquitous, with abrogation of G2 arrest leading to entry into
mitosis even after irradiation [12,15]. Cell cycle analysis at 48 h
post-irradiation for HeLa and HCT116 are in line with expected
results. Radiosensitization in HeLa cells corresponds to an increase
in both .4N and subG1 population (Fig. 6), while the p53-positive
HCT116 shows resistance to cell cycle perturbation at 48 h.
Results for HN3 and HN5 are more difficult to interpret. Little
observable difference is seen for HN5 which is highly sensitive to
sub-G1 accumulation due to NVP-AUY922 alone (Fig. 6; Fig.
S5B). HN3 cells have a high baseline .4N population, with NVP-
AUY922 actually reducing radiation-induced .4N cells, corre-
sponding to an increase in the G1 cell population. How this NVP-
AUY922-mediated intervention in radiation-induced .4N popu-
lation formation may contribute, either positively or negatively, to
survival is not known. Unlike the ubiquitous effects observed for
client protein depletion, DSB repair and chromosomal fragmen-
tation, cell cycle data for NVP-AUY922 in combination with
radiation is significantly more variable across cell lines. Cell cycle
data suggests the outcome of the ubiquitous HSP90 effects
indicated may not result in a uniform radiosensitization linked
end point, this represents an aspect of radiosensitization which
warrants further study in HNSCC cell lines.
The present preclinical work shows that NVP-AUY922 is a
promising candidate for translational clinical studies in conjunc-
tion with external beam radiotherapy in head and neck squamous
cell carcinoma. The current body of literature strongly supports
the potential of HSP90 inhibition to enhance the therapeutic
window between normal tissue and that of malignant neoplasms.
Of potential substantial benefit is the diversity of downstream
effects mediated via a single targeted agent. In the sphere of
chemoradiotherapy, the benefit of simultaneously disabling
prosurvival pathways, checkpoint arrest and DNA damage repair
is one of considerable promise in improving clinical outcomes.
Although considered less of a concern in this multi-targeted
approach, ErbB3 expression (which has been shown to be
overexpressed in HNSCC) has been linked to resistance to 17-
DMAG-induced radiosensitization [9]. In conjunction with cell
cycle effects observed for the HNSCC cell lines HN3 and HN5
and cell line-dependent mitotic accumulation in HN5 and HeLa
cells observed in this paper, this highlights the importance of
continued investigation into the genetic and epigenetic factors
related to HSP90-mediated radiosensitization. In conclusion, the
data shown here identify NVP-AUY922 as the most potent
HSP90-targeted radiosensitizer currently available both in vitro and
in vivo and, as such, the most promising candidate studied to date
for future clinical development.
Supporting Information
Figure S1 Tumor volumes corresponding to NVP-
AUY922 for 10 mg/kg plus radiation in HN3 human
HNSCC murine xenograft model. (A) Clonogenic cell
survival of HeLa, HCT116, HN3 and HN5 cell lines due to
24 h pre-treatment with 100 nM 17-AAG or NVP-AUY922 at the
concentrations indicated followed by subsequent 2 Gy irradiation
or mock-irradiation. Colony formation was determined at 10 to 14
days after irradiation and surviving fractions calculated relative to
plating efficiencies for vehicle only non-irradiated cells. (B) HN3
cells were allowed to achieve a tumor volume of 5–8 mm after
implantation in the right flank and evenly distributed into four
treatment groups with matching average tumor volumes; vehicle
only control (n=8); NVP-AUY922, three doses of 10 mg/kg each
(n=9); 9 Gy ionising radiation fractionated in three doses of 3 Gy
(n=9); NVP-AUY922 and ionising radiation (n=8). Actual tumor
volumes used to calculate baseline tumor volumes in figure 1 are
shown.
(PDF)
Figure S2 HSP72 upregulation due to radiation in
combination with NVP-AUY922. (A) Triplicate western blot
data used for densitometric quantitiation as shown in Figure 3B.
(B) HN5 cells were pre-treated with NVP-AUY922 for 24 h at the
concentrations indicated. Cells were irradiated with 4 Gy or
10 Gy and 4 h later whole cell lysates harvested and probed for
HSP72 by western blot. (C) HeLa cells were irradiated with 4 Gy
of radiation delivered at the 0 hour time point. At the subsequent
time points indicated whole cell lysates were harvested and probed
for HSP72. c-tubulin and GAPDH were probed as loading
controls as indicated.
(PDF)
Figure S3 NVP-AUY922 delays Rad51 foci formation
and resolution of phospho-H2ax foci. HN5 and HCT116
cells were plated in glass bottom dishes and after attachment
exposed to NVP-AUY922 or DMSO control. 24 h post drug-
treatment cells were mock irradiated or irradiated with 4 Gy, 4 h
and 24 h post-irradiation cells were fixed and stained for dsDNA
breaks using anti-phospho-H2ax and anti-Rad51 with TO-PRO-3
as nuclear counter stain. (A) The average phospho-H2ax foci per-
cell in HN5 and HCT116 cell lines at 4 h and 24 h post
irradiation was quantified, with data shown for quantification of
150 cells in a single experiment. (B) Rad51 foci were quantified in
HN5 and HCT116, with nuclei containing greater than 3 foci
scored as positive. Foci formation in HN5 shown for one
independent experiment and two for HCT116. (C) Quantification
of average Rad51 foci per nuclei shown for HeLa, HN3, HN5 and
HCT116 (calculated from the same dataset used in B above and
Fig. 4C). HeLa and HN3 data shown as average of two
independent experiments, HN5 and HCT116 data shown from
one experiment.
(PDF)
Figure S4 NVP-AUY922 in combination with radiation
increases occurrence of pan-phospho-H2ax stained
micronuclei in HN5 and HCT116 cell lines. HN5 and
HCT116 cells were treated with vehicle only or NVP-AUY922 as
indicated for 24 h before mock irradiation or irradiation with
4 Gy. 24 h post-irradiation cells were fixed and stained for
phospho-H2ax with TOPRO-3 as nuclear counterstain. Nuclei
with associated pan-phospho-H2ax positive micronuclei were
quantified for a minimum of 150 cells. Data shown as single
experiment.
(PDF)
Figure S5 NVP-AUY922 induces both increased entry
and delayed exit from mitosis due to ionising radiation.
Cells were exposed to the NVP-AUY922 concentrations indicated
for 16 h before mock irradiation or irradiation with 4 Gy. Cells
were fixed at 9 h and 48 h post-irradiation before (A) staining for
the mitotic marker phospho-histone H3 and (B) DNA content with
propidium iodide and quantification of G1, S and G2 populations
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experiments each recording at least 10,000 events.
(PDF)
Acknowledgments
We would like to thank Novartis for kindly supplying NVP-AUY922 for
experimental study.
Author Contributions
Conceived and designed the experiments: SZ MM KJH. Performed the
experiments: SZ MM. Analyzed the data: SZ MM SAB SAE PW CMN
RAH KJH. Wrote the paper: SZ MM SAE PW CMN RAH KJH.
References
1. Pearl LH, Prodromou C, Workman P (2008) The Hsp90 molecular chaperone:
an open and shut case for treatment. Biochem J 410: 439–453.
2. Pearl LH, Prodromou C (2006) Structure and mechanism of the Hsp90
molecular chaperone machinery. Annu Rev Biochem 75: 271–294.
3. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic
HSP90 complex in cancer. Nat Rev Cancer 10: 537–549.
4. Workman P, Burrows F, Neckers L, Rosen N (2007) Drugging the cancer
chaperone HSP90: combinatorial therapeutic exploitation of oncogene addic-
tion and tumor stress. Ann N Y Acad Sci 1113: 202–216.
5. Oda T, Hayano T, Miyaso H, Takahashi N, Yamashita T (2007) Hsp90
regulates the Fanconi anemia DNA damage response pathway. Blood 109:
5016–5026.
6. Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, et al. (2006)
Chaperoning checkpoint kinase 1 (CHK1), an Hsp90 client, with purified
chaperones. J Biol Chem 281: 2989–2998.
7. Camphausen K, Tofilon PJ (2007) Inhibition of Hsp90: a multitarget approach
to radiosensitization. Clin Cancer Res 13: 4326–4330.
8. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ (2003)
Enhanced cell killing induced by the combination of radiation and the heat
shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a
multitarget approach to radiosensitization. Clin Cancer Res 9: 3749–3755.
9. Dote H, Cerna D, Burgan WE, Camphausen K, Tofilon PJ (2005) ErbB3
expression predicts tumor cell radiosensitization induced by Hsp90 inhibition.
Cancer Res 65: 6967–6975.
10. Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, et al. (2010) BIIB021, a
novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to
radiotherapy. Int J Cancer 126: 1216–1225.
11. Machida H, Nakajima S, Shikano N, Nishio J, Okada S, et al. (2005) Heat shock
protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin potentiates the
radiation response of tumor cells grown as monolayer cultures and spheroids by
inducing apoptosis. Cancer Sci 96: 911–917.
12. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, et al. (2004) Enhanced
tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the
Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Clin Cancer Res 10: 8077–8084.
13. Machida H, Matsumoto Y, Shirai M, Kubota N (2003) Geldanamycin, an
inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol
79: 973–980.
14. Matsumoto Y, Machida H, Kubota N (2005) Preferential sensitization of tumor
cells to radiation by heat shock protein 90 inhibitor geldanamycin. J Radiat Res
46: 215–221.
15. Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG (2008)
Geldanamycin promotes premature mitotic entry and micronucleation in
irradiated p53/p21 deficient colon carcinoma cells. Oncogene 27: 5567–5577.
16. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, et al. (2003)
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in
vitro and in vivo radiation response of cervical tumor cells via the heat shock
protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:
8984–8995.
17. Dungey FA, Caldecott KW, Chalmers AJ (2009) Enhanced radiosensitization of
human glioma cells by combining inhibition of poly(ADP-ribose) polymerase
with inhibition of heat shock protein 90. Mol Cancer Ther 8: 2243–2254.
18. Kabakov AE, Makarova YM, Malyutina YV (2008) Radiosensitization of
human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-
17-demethoxygeldanamycin. Int J Radiat Oncol Biol Phys 71: 858–865.
19. Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den
Dunnen WF, et al. (2010) 89Zr-Bevacizumab PET of Early Antiangiogenic
Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. Journal of
nuclear medicine : official publication, Society of Nuclear Medicine.
20. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, et al. (2008) NVP-
AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor
growth, angiogenesis, and metastasis. Cancer Res 68: 2850–2860.
21. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, et al.
(2010) Tanespimycin monotherapy in relapsed multiple myeloma: results of a
phase 1 dose-escalation study. Br J Haematol 150: 438–445.
22. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, et al. (2007) A phase I
study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients
with solid tumors: a Children’s Oncology Group study. Clin Cancer Res 13:
1789–1793.
23. Banerji U, O’Donnell A, Scurr M, Pacey S, Stapleton S, et al. (2005) Phase I
pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethox-
ygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:
4152–4161.
24. Pacey S, Gore M, Chao D, Banerji U, Larkin J, et al. (2010) A Phase II trial of
17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients
with metastatic melanoma. Investigational new drugs. DOI: 10.1007/s10637-
010-9493-4.
25. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A
phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with
hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940–7946.
26. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, et al. (2006) A
phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with
papillary and clear cell renal cell carcinoma. Investigational new drugs 24:
543–546.
27. Pacey S, Wilson RH, Walton MI, Eatock M, Hardcastle A, et al. (2011) A Phase
I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given
intravenously to patients with advanced, solid tumors. Clin Cancer Res 17:
1561–1570.
28. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, et al. (2008) 4,5-
diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the
treatment of cancer. J Med Chem 51: 196–218.
29. Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, et al. (2008) NVP-
AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in
preclinical breast cancer models. Breast Cancer Res 10: R33.
30. Stu ¨hmer T, Zo ¨llinger A, Siegmund D, Chatterjee M, Grella E, et al. (2008)
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-
AUY922 in multiple myeloma. Leukemia 22: 1604–1612.
31. Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, et al. (2010) Mechanistic
evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric
glioblastoma. Mol Cancer Ther 9: 1219–1233.
32. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, et al. (2010)
Guidelines for the welfare and use of animals in cancer research. Br J Cancer
102: 1555–1577.
33. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, et al. (2005)
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90
molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in
human ovarian cancer xenograft models. Clin Cancer Res 11: 7023–7032.
34. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, et al. (2004) Cell
death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825–2837.
35. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, et al. (2004) Mitotic
catastrophe constitutes a special case of apoptosis whose suppression entails
aneuploidy. Oncogene 23: 4362–4370.
36. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Che `ne P, et al. (2010)
Preclinical antitumor activity of the orally available heat shock protein 90
inhibitor NVP-BEP800. Mol Cancer Ther 9: 906–919.
37. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, et al. (2006) Development of
17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-
504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 103:
17408–17413.
38. Stingl L, Stu ¨hmer T, Chatterjee M, Jensen MR, Flentje M, et al. (2010) Novel
HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells
through cell-cycle impairment, increased DNA damage and repair protraction.
Br J Cancer 102: 1578–1591.
39. Ha K, Fiskus W, Rao R, Balusu R, Venkannagari S, et al. (2011) Hsp90
inhibitor mediated disruption of chaperone association of ATR with Hsp90
sensitizes cancer cells to DNA damage. Mol Cancer Ther.
40. Oude Munnink TH, Korte MA, Nagengast WB, Timmer-Bosscha H,
Schro ¨der CP, et al. (2010) (89)Zr-trastuzumab PET visualises HER2
downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour
xenograft. Eur J Cancer 46: 678–684.
41. Noguchi M, Yu D, Hirayama R, Ninomiya Y, Sekine E, et al. (2006) Inhibition
of homologous recombination repair in irradiated tumor cells pretreated with
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys
Res Commun 351: 658–663.
42. Merwald H, Kokesch C, Klosner G, Matsui M, Trautinger F (2006) Induction of
the 72-kilodalton heat shock protein and protection from ultraviolet B-induced
cell death in human keratinocytes by repetitive exposure to heat shock or 15-
deoxy-delta(12,14)-prostaglandin J2. Cell Stress Chaperones 11: 81–88.
43. Gabai VL, O’Callaghan-Sunol C, Meng L, Sherman MY, Yaglom J (2008)
Triggering senescence programs suppresses Chk1 kinase and sensitizes cells to
genotoxic stresses. Cancer Res 68: 1834–1842.
Mechanisms of Radiosensitization by NVP-AUY922
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e3543644. Gabai V, Sherman M, Yaglom J (2010) HSP72 depletion suppresses
gammaH2AX activation by genotoxic stresses via p53/p21 signaling. Oncogene
29: 1952–1962.
45. Yao Q, Weigel B, Kersey J (2007) Synergism between etoposide and 17-AAG in
leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and
Rad51. Clin Cancer Res 13: 1591–1600.
46. Lobrich M, Jeggo P (2007) The impact of a negligent G2/M checkpoint on
genomic instability and cancer induction. Nat Rev Cancer 7: 861–869.
47. Deckbar D, Birraux J, Krempler A, Tchouandong L, Beucher A, et al. (2007)
Chromosome breakage after G2 checkpoint release. J Cell Biol 176: 749–755.
48. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, et al. (2003)
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
J Biol Chem 278: 52572–52577.
49. Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, et al. (2008)
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by
interfering with base excision and ATM-mediated DNA repair. Mol Cancer
Ther 7: 1985–1992.
50. Schwock J, Pham NA, Cao MP, Hedley DW (2008) Efficacy of Hsp90 inhibition
for induction of apoptosis and inhibition of growth in cervical carcinoma cells in
vitro and in vivo. Cancer Chemother Pharmacol 61: 669–681.
51. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, et al. (2009) The aurora B
kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and
induces mitotic catastrophe. Cell Cycle 8: 3172–3181.
Mechanisms of Radiosensitization by NVP-AUY922
PLoS ONE | www.plosone.org 13 April 2012 | Volume 7 | Issue 4 | e35436